Conservative Management of Severe Seizure-Induced Rhabdomyolysis and AKI

This single-patient case illustrates that markedly elevated creatine kinase and creatinine do not by themselves mandate kidney replacement therapy when hemodynamics, urine output, and biochemistry remain stable, and it reinforces the pharmacist's role in renal dose adjustment.

levetiracetambumetaniderhabdomyolysisacute kidney injuryseizurerenal dose adjustmentnephrologycase reportnormal salinekidney replacement therapy Nephrology / Renal Pharmacy

Background Information

Rhabdomyolysis from seizures requires careful nephrology management to prevent AKI.

Seizure-induced rhabdomyolysis poses a risk for acute kidney injury (AKI), necessitating careful medical management to prevent further complications. Aggressive intravenous (IV) fluid resuscitation improved kidney function without life-threatening complications, indicating effective conservative management. This case highlights the importance of nephrology-guided management in rhabdomyolysis, showing that in select patients, conservative measures may preclude the need for renal replacement therapy. Timely and appropriate hydration can effectively manage seizure-induced rhabdomyolysis without requiring dialysis.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Kaur H, Kennedy HH, Nobakht N

Citation: Kaur H, Kennedy HH, Nobakht N Seizure-Induced Rhabdomyolysis Complicated by Acute Kidney Injury: A Case Report. The American journal of case reports. 2026;27:e951097. doi:10.12659/AJCR.951097

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →